Singapore Med J. 2017 Aug;58(8):473-480. doi: 10.11622/smedj.2017082.
The first clinical guidelines for male lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) were published in 2005. An update is urgently needed in view of BPH being recognised as one of ten chronic illnesses by the Ministry of Health, Singapore. This review summarises the definition of BPH and the epidemiology of male LUTS/BPH in Singapore. BPH can be phenotyped with noninvasive transabdominal ultrasonography, according to intravesical prostatic protrusion and prostate volume, and classified according to severity (staging) for individualised treatment. At the initial evaluation, the majority of patients (59%) can be managed with fluid adjustment, exercise and diet; 32% with medications, using alpha blockers and/or 5-alpha reductase inhibitors for prostates weighing more than 30 g; and 9% with surgical intervention for more advanced disease. The 2015 guidelines comprise updated evidence that will help family medicine practitioners and specialists manage this common ailment more cost-effectively.
男性下尿路症状(LUTS)/良性前列腺增生(BPH)的首个临床指南于2005年发布。鉴于新加坡卫生部已将BPH认定为十大慢性病之一,因此迫切需要对该指南进行更新。本综述总结了BPH的定义以及新加坡男性LUTS/BPH的流行病学情况。根据膀胱内前列腺突出度和前列腺体积,可通过无创经腹超声对BPH进行表型分析,并根据严重程度(分期)进行分类,以实现个体化治疗。在初始评估时,大多数患者(59%)可通过调整液体摄入、运动和饮食进行管理;32%的患者使用药物治疗,对于前列腺重量超过30 g的患者,使用α受体阻滞剂和/或5-α还原酶抑制剂;9%的患者因病情更严重需要手术干预。2015年版指南包含了更新后的证据,将有助于家庭医生和专科医生更经济有效地管理这种常见疾病。